Three months after Myogen Inc.'s lead drug candidate for heart failure, enoximone, missed statistical significance in the primary endpoint of a Phase III trial - an event the company blamed on unexpected improvements in patients given placebo - the compound has failed in top-line results from two more Phase III studies. (BioWorld Today)

A little more than two months after filing for approval of Vivitrex, Alkermes Inc. partnered the alcohol-dependence drug with Cephalon Inc. in a 50-50 profit-sharing deal worth an additional $480 million in up-front and milestone payments. (BioWorld Today)